Product Description
RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor. (Sourced from: https://www.lls.org/research/rgenta-therapeutics-joins-leukemia-lymphoma-society-therapy-acceleration-program)
Mechanisms of Action: MYB Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rgenta Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for RNA-targeting MYB inhibitor - Rgenta](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|